Country sites EN Home About Products Investors Sustainability Newsroom Careers Contact Hikma Key financial data $ million 1H21 1H20 Change Constant currency change Revenue 1,216 1,132 7% 7% Core revenue 1,216 1,132 7% 7% Gross profit 616 577 7% 7% Core gross profit 616 577 7% 7% Operating profit 326 297 10% 15% Core operating profit 309 284 9% 15% EBITDA 358 328 9% 14% Core EBITDA 358 328 9% 14% Profit attributable to shareholders 248 212 17% 26% Core profit attributable to shareholders 223 205 9% 18% Basic earnings per share (cents) 107.4 87.6 23% 32% Core basic earnings per share (cents) 96.5 85.3 13% 23% Interim dividend per share (cents) 18.0 16.0 13% - Cash flow from operating activities 224 292 (23)% - Investors Financial information Back to top Useful links About Products Investors News Careers Contact Worldwide Leadership Stay in touch Subscribe to our newsletter Follow us instagram Created with Sketch. © Hikma Pharmaceuticals PLC 2021 Terms of use Cookie policy Disclaimer Privacy policy Community guidelines Our website uses cookies to improve your experience. Some of the cookies we use are essential for parts of our website to operate. By using our website without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.